NEW YORK (GenomeWeb News) – Bruker and the University of Victoria-Genome British Columbia Proteomics Centre said today that they are collaborating on developing high-throughput iMALDI mass spectrometry-based assays for determining genetic hemoglobin variants and diabetes risk.

The assays, which combine peptide immunoenrichment with mass spectrometry for improved throughput and sensitivity, will be developed to run on Bruker's MALDI Biotyper clinical mass spectrometry platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.